Drug resistance in cancer immunotherapy : new strategies to improve checkpoint inhibitor therapies
© The Author(s) 2019..
Recent advances in pharmacological immune modulation against tumor cells has dramatically changed the paradigm of cancer treatment. Checkpoint inhibitor therapy is a form of cancer immunotherapy already in clinical setting but also under active basic and clinical investigation. Nevertheless, some patients are primary unresponsive or develop ulterior resistance to these family of drugs. This review aims to update the basic molecular mechanism of resistance as well as the current strategies for checkpoint inhibitor selection in order to propose new approaches to individualize the use of these novel therapies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2 |
|---|---|
| Enthalten in: |
Cancer drug resistance (Alhambra, Calif.) - 2(2019), 4 vom: 01., Seite 980-993 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rodriguez-Pascual, Jesus [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Checkpoint inhibitors |
|---|
| Anmerkungen: |
Date Revised 19.05.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.20517/cdr.2019.61 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341050679 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341050679 | ||
| 003 | DE-627 | ||
| 005 | 20231226010859.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.20517/cdr.2019.61 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1136.xml |
| 035 | |a (DE-627)NLM341050679 | ||
| 035 | |a (NLM)35582274 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rodriguez-Pascual, Jesus |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Drug resistance in cancer immunotherapy |b new strategies to improve checkpoint inhibitor therapies |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 19.05.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2019. | ||
| 520 | |a Recent advances in pharmacological immune modulation against tumor cells has dramatically changed the paradigm of cancer treatment. Checkpoint inhibitor therapy is a form of cancer immunotherapy already in clinical setting but also under active basic and clinical investigation. Nevertheless, some patients are primary unresponsive or develop ulterior resistance to these family of drugs. This review aims to update the basic molecular mechanism of resistance as well as the current strategies for checkpoint inhibitor selection in order to propose new approaches to individualize the use of these novel therapies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a checkpoint inhibitors | |
| 650 | 4 | |a cytotoxic T-lymphocyte antigen 4 | |
| 650 | 4 | |a programmed death ligand-1 | |
| 650 | 4 | |a programmed death receptor-1 | |
| 700 | 1 | |a Ayuso-Sacido, Angel |e verfasserin |4 aut | |
| 700 | 1 | |a Belda-Iniesta, Cristobal |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer drug resistance (Alhambra, Calif.) |d 2018 |g 2(2019), 4 vom: 01., Seite 980-993 |w (DE-627)NLM292424043 |x 2578-532X |7 nnns |
| 773 | 1 | 8 | |g volume:2 |g year:2019 |g number:4 |g day:01 |g pages:980-993 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.20517/cdr.2019.61 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 2 |j 2019 |e 4 |b 01 |h 980-993 | ||